Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation

Transplant Infectious Disease

Volumn 10, Issue 4, 2008, Pages 290-293

  Neuburger, S ^a   Massenkeil, G ^b   Seibold, M ^c   Lutz, C ^a   Tamm, I ^a   Le Coutre, P ^a   Graf, B ^a   Doerken, B ^a   Arnold, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Cutaneous; Fusarium; Infections; Neutropenia; Stem cell; Terbinafine; Transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TERBINAFINE; VORICONAZOLE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; DISSEMINATED CUTANEOUS FUSARIOSIS; DRUG SUBSTITUTION; FEMALE; FEVER; FUSARIUM PROLIFERATUM; GRAFT REJECTION; GRANULOCYTOPENIA; HUMAN; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN ABSCESS; SKIN BIOPSY; SKIN INFLAMMATION; SKIN NODULE; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DERMATOMYCOSES; DRUG THERAPY, COMBINATION; FEMALE; FUSARIUM; HUMANS; MIDDLE AGED; NAPHTHALENES; NEUTROPENIA; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 47849092581     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00296.x     Document Type: Article

References (20)

1. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34 : 909 917.
2. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003 98 : 315 319.
3. Boutati EI, Anaissie E. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood 1997 90 : 999 1008.
4. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004 38 : 1237 1242.
5. Arikan S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2002 46 : 3084 3087.
6. Consigny S, Dhedin N, Datry A, et al. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003 37 : 311 313.
7. Rodriguez CA, Lujan-Zilbermann J, Woodard P, et al. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003 31 : 411 412.
8. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003 36 : 1122 1131.
9. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leukemia Lymphoma 2004 45 : 139 141.
10. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patients with acute leukaemia treated with caspofungin. Clin Infect Dis 2003 36 : 1349 1350.
11. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Reviews of anti-infective agents. Clin Infect Dis 2003 36 : 225 234.
12. Pfaller MA, Messer SA, et al., and the SENTRY Participants Group. Antifungal activity of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 46 : 1032 1037.
13. Gupta S, Almyroudis NG, Battiwalla M, et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007 9 : 156 160.
14. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006 42 : 1398 1403.
15. Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of Fusarium proliferatum with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004 23 : 1451 1454.
16. Reuben A, Anaissie E, Nelson PE, et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother 1989 33 : 1647 1649.
17. Rotowa NA, Shadomy HJ, Shadomy S. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses 1990 33 : 203 211.
18. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004 83 : 394 397.
19. Nedelman JR, Gibiansky E, Robbins BA, et al. Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J Clin Pharmacol 1996 36 : 452 461.
20. Schmitt HJ, Andrade J, Edwards F, et al. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1990 9 : 832 835.